Metabolic study of trimetazidine using ultrahigh performance liquid chromatographytandem mass spectrometry


  • Kamila Chomanicova Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia
  • Élida Alechaga Silva Catalonian Anti-Doping Laboratory, Hospital del Mar Institute for Medical Research, Barcelona, Spain
  • Rosa Ventura Alemany Catalonian Anti-Doping Laboratory, Hospital del Mar Institute for Medical Research, Barcelona, Spain



Trimetazidine, Liquid chromatography, Mass spectrometry, Excretion profiles, Metabolites


In the present study, the application of ultra-high performance liquid chromatography-tandem mass spectrometry allowed us to study of known-as well as hitherto unknown-trimetazidine (TMZ) metabolites in human urine and to propose their renal excretion profiles. Urine samples from a healthy volunteer were analyzed at baseline and at 0-4 h, 4-8 h, 8-12 h, and 12-24 h after a single dose of TMZ. A dilute-and-shoot procedure was used as sample treatment before separation. Full-scan spectra of possible metabolites were acquired. Additionally, product ion scan spectra of precursor ions of interest were also acquired at two collision energies. Intact TMZ was a major excretion product, with a maximum concentration at 4-8 h after administration. Moreover, five minor metabolites were observed, namely trimetazidine-N-oxide (M1), N-formyl trimetazidine (M2), desmethyl-trimetazidine O-sulfate (M3), desmethyl-trimetazidine O-glucuronide (M4), and desmethyl-trimetazidine-N-oxide-O-glucuronide (M5). Metabolite M5 has not previously been reported. Excretion curves were constructed based on the chromatographic peak areas of specific mass transitions (precursor ion > product ion) related to each of the detected metabolites.


Download data is not yet available.


Barré J, Ledudal P, Oosterhuis B, Brakenhoff JP, Wilkens G, Sollie FA, et al. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. Biopharm Drug Dispos. 2003;24(4):159-164.

Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008;15(5):533-540.

Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2017;3(3):CD003614.

Dézsi CA. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence. Am J Ther. 2016;23(3):e871-979.

Dong Y, Yan K, Ma Y, Wang S, He G, Deng J, et al. A Sensitive Dilute-and-Shoot Approach for the Simultaneous Screening of 71 Stimulants and 7 Metabolites in Human Urine by LC-MS-MS with Dynamic MRM. J Chromatogr Sci. 2015;53(9):1528-1535.

El-Alfy W, Ismaiel OA, El-Mammli MY, Shalaby A. Determination of Atenolol and Trimetazidine in Pharmaceutical Tablets and Human Urine Using a High Performance Liquid Chromatography-Photo Diode Array Detection Method. Int J Anal Chem. 2019;2:1-8.

Fan Q, Niu Z, Ma L. Meta-analysis of trimetazidine treatment for cardiomyopathy. Biosci Rep. 2018;38(3): BSR20171583.

Fay L, Michel G, Goupit P, Harpey C, Prost M. Determination of trimetazidine in biological fluids by gas chromatography-mass spectrometry. J Chromatogr. 1989;490(1):198-205.

Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27(8):942-948.

Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a Meta-Analysis of Randomised Controlled Trials in Heart Failure. Heart. 2011;97(4):278-286.

Ghoneim MM, Khashaba PY, Beltagi AM. Determination of trimetazidine HCl by adsorptive stripping square-wave voltammetry at a glassy carbon electrode. J Pharm Biomed Anal. 2002;27(1-2):235-241.

Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol. 2011;34(6):395-400.

Huang CQ, Dong BR. Effects of trimetazidine for coronary heart failure: a systematic review. Chin J Evid Based Med. 2007;7:37-44.

Jackson PJ, Brownsill RD, Taylor AR, Resplandy G, Walther B, Schwietert HR. Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica. 1996;26(2):221-228.

Jarek A, Wójtowicz M, Kwiatkowska D, Kita M, Turek-Lepa E, Chajewska K, et al. The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration. Drug Test Anal. 2014;6(11-12):1191-1196.

Jefri Puspitasari AD, Talpaneni JSR, Tjandrawinata RR. Identification and control of unspecified impurity in trimetazidine dihydrochloride tablet formulation. IOP Conf Ser: Mater Sci Eng. 2018;349:012029.

Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase. Circ Res. 2000;86:580-588.

Lopatin Y. Trimetazidine in the new 2016 European guidelines on heart failure and beyond. Heart Metab. 2016;71:23-26.

Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin. 2003;19(7):661-672.

Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9(6):555-566.

Sigmund G, Koch A, Orlovius AK, Guddat S, Thomas A, Schänzer W, et al. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches. Drug Test Anal . 2014;6(11-12):1197-1205.

Tsioufis K, Andrikopoulos G, Manolis A. Trimetazidine and cardioprotection: facts and perspectives. Angiology. 2015;66(3):204-10.

Winter JL, Castro PF, Quintana JC, Altamirano R, Enriquez A, Verdejo HE, et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. J Card Fail. 2014;20(3):149-154.

World Anti-Doping Agency. WADA. International standard. 2014 Prohibited List. Montreal, Canada: WADA; 2014.

World Anti-Doping Agency. WADA. International standard. 2021 Prohibited List. Montreal, Canada: WADA ; 2021.

Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59(10):913-922.

Zhou G, Tan ZR, Ouyang DS, Chen Y, Guo D, Xie HT, et al. Development and validation of a simple and sensitive liquid chromatography-tandem mass spectrometry method for quantifying trimetazidine in human plasma. Clin Exp Pharmacol Physiol. 2010;37(4):501-505.






Original Article

How to Cite

Metabolic study of trimetazidine using ultrahigh performance liquid chromatographytandem mass spectrometry. (2023). Brazilian Journal of Pharmaceutical Sciences, 59.